Cartesian Therapeutics, Inc.
RNAC
$11.04
-$0.21-1.87%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 298.00K | 1.10M | -759.00K | 387.00K | 33.45M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 298.00K | 1.10M | -759.00K | 387.00K | 33.45M |
| Cost of Revenue | 1.81M | 1.28M | 11.31M | 11.40M | 776.00K |
| Gross Profit | -1.51M | -175.00K | -12.07M | -11.01M | 32.67M |
| SG&A Expenses | 7.24M | 8.32M | 7.09M | 6.56M | 7.03M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.11M | 22.99M | 18.39M | 17.96M | 19.69M |
| Operating Income | -21.81M | -21.89M | -19.15M | -17.58M | 13.76M |
| Income Before Tax | 15.89M | -17.71M | -9.97M | -24.18M | 13.84M |
| Income Tax Expenses | -- | -- | 287.00K | -- | -- |
| Earnings from Continuing Operations | 15.89M | -17.71M | -10.25M | -24.18M | 13.84M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 15.89M | -17.71M | -10.25M | -24.18M | 13.84M |
| EBIT | -21.81M | -21.89M | -19.15M | -17.58M | 13.76M |
| EBITDA | -21.22M | -20.73M | -18.67M | -17.29M | 13.95M |
| EPS Basic | 0.51 | -0.58 | -0.40 | -1.13 | 0.58 |
| Normalized Basic EPS | -0.47 | -0.44 | -0.43 | -0.26 | 0.42 |
| EPS Diluted | 0.50 | -0.58 | -0.42 | -1.13 | 0.54 |
| Normalized Diluted EPS | -0.46 | -0.44 | -0.43 | -0.26 | 0.40 |
| Average Basic Shares Outstanding | 25.98M | 25.90M | 25.42M | 21.47M | 16.72M |
| Average Diluted Shares Outstanding | 26.45M | 25.90M | 25.42M | 21.47M | 17.79M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |